HURA (TuHURA Biosciences) Cash-to-Debt : 62.35 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TuHURA Biosciences's cash to debt ratio for the quarter that ended in Dec. 2024 was 62.35.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TuHURA Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for TuHURA Biosciences's Cash-to-Debt or its related term are showing as below:

HURA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.56 Med: 35.48 Max: 103.28
Current: 62.35

During the past 4 years, TuHURA Biosciences's highest Cash to Debt Ratio was 103.28. The lowest was 1.56. And the median was 35.48.

HURA's Cash-to-Debt is ranked better than
74.16% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs HURA: 62.35

TuHURA Biosciences Cash-to-Debt Historical Data

The historical data trend for TuHURA Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

TuHURA Biosciences Cash-to-Debt Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

8.61

103.28

1.56

62.35

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial				1.56	0.62	0.75	No Debt	62.35

Competitive Comparison of TuHURA Biosciences's Cash-to-Debt

For the Biotechnology subindustry, TuHURA Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

TuHURA Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

TuHURA Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.657	/	(0.16	+	0.043)
	=	62.35

TuHURA Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.657	/	(0.16	+	0.043)
	=	62.35

TuHURA Biosciences (NAS:HURA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

TuHURA Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.